KYORIN Pharmaceutical Co.,Ltd. [4569.T]
TOKYO, Mar 31 (Pulse News Wire) – Kyorin Pharmaceutical CO.,LTD. (4569.T) exercised its option rights based on an agreement signed with BIODOL Therapeutics in January 2025, securing exclusive development, manufacturing, and sales rights for pain treatment candidate BDT272 in Japan, South Korea, and Taiwan.
In exchange, KYORIN will pay up to €¥79 million, including an upfront fee and milestone payments upon achieving certain net sales targets, along with royalties tied to future sales. BDT272 is expected to effectively manage neuropathic pain by inhibiting FLT3, a receptor tyrosine kinase family member deeply involved in pain onset and persistence. KYORIN aims to address unmet medical needs through innovative drug research, particularly in the pain management field. The company anticipates providing patients suffering from pain with additional therapeutic options through the development and sale of BDT272.
Regarding the impact on fiscal 2026 linked performance forecasts, KYORIN plans to record the upfront payment as part of selling expenses and general administrative costs, including research and development expenses, within the same fiscal period. Any significant developments requiring timely disclosure will be communicated promptly. KYORIN's collaboration with BIODOL builds on previous findings published in Nature Communications, which demonstrated FLT3’s role in neuropathic pain and showed that FLT3 inhibition could maintain opioid analgesia while reducing opioid tolerance and hyperalgesia. With four patents in their portfolio, BIODOL receives support from various French institutions and legal advice from MCE Carrel law firm.
🟢 Confidence: High AI-translated content.